Methods. In a randomised, controlled 2-arm effectiveness trial, 4233 patients with a general with FF/VI improved ACT from baseline by 4·4 points compared to 2·8 in the UC group. 87 This was consistent across the duration of the study. There was no significant difference in 88 asthma exacerbations, or in asthma-related primary or secondary care contacts. Pneumonia 89 was uncommon, with no differences between groups; there was no difference in other serious 90 adverse events. The study is registered on clinicaltrials.gov as NCT01706198. The study showed that in these patients with a general practitioners diagnosis of asthma, 
Results

256
Study Population 257 4725 subjects were enrolled into the study of which 4233 were randomised (FF/VI 2114, 258 usual care 2119) and form the total study population (Fig 1) . Of these, 3026 subjects (71%) 259 had an ACT score of < 20 at baseline and formed the Primary Effectiveness Analysis (PEA) Table 2 shows the distribution of serious adverse events based on the treatment patients were 330 on when the event was reported. The incidence of SAE of pneumonia by the treatment taken 331 at the time (i.e. taking treatment modification into account) was low, with the same number 332 of events on FF/VI and usual care (Table 2 ). When analysing pneumonia according to 333 randomised group, patients in the FF/VI group had a slightly higher numerical incidence of 334 pneumonias compared to the UC group (23 vs 16; incidence ratio 1·4; 95% CI 0·8 to 2·7).
335
There was no difference in the pre-specified SAE of special interest, time to first on-336 treatment pneumonia (hazard ratio 1·45 (95% CI 0·77 to 2·74) p=0·255). 
